By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues jumped 25 percent and its non-GAAP net income more than doubled on strong clinical sales.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $70.2 million for the three months ended Sept. 30, compared to $56.1 million for the third quarter of 2010. It beat analysts' consensus estimate for revenues of $68.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.